相关实验视频

Updated: Jan 12, 2026

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

从EGFR突变肺腺癌转变为小细胞肺癌:从克隆进化到谱系重编程

Haoxin Wang¹, Nan Gao¹, Lu Wang¹

¹Shandong University of Traditional Chinese Medicine, Jinan, Shandong, China.

Cancer treatment reviews

|November 8, 2025

概括

患有EGFR突变的肺腺癌在治疗后可以转化为攻击性的小细胞肺癌. 这种转变涉及遗传变化和EGFR依赖性丧失,导致预后不佳.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
遗传学遗传学是一个

背景情况:

EGFR突变肺腺癌 (LUAD) 可以通过转化为小细胞肺癌 (SCLC) 来获得针对性治疗的耐药性.
这种转化后SCLC (SCLC-AT) 变体呈现出积极的临床过程和不良预后.
SCLC-AT保留了EGFR突变,但降低了EGFR蛋白质表达的调节,失去EGFR信号依赖,并获得神经内分泌表型,通常具有双TP53和RB1失活.

研究的目的:

检查驱动从EGFR突变LUAD转变为SCLC的分子机制.
整合克隆进化和谱系重编程概念来理解这种转变.
审查最近在确定细胞起源,遗传/表观遗传重编程和信号通路改变方面的进展.

主要方法:

综合克隆进化和谱系重编程的当前文献的审查.
对遗传和表观遗传重编程事件的分析.
在LUAD转化为SCLC过程中检查信号通路的变化.

主要成果:

转变涉及克隆进化和谱系重编程,导致EGFR依赖性丧失和获得神经内分泌表型.
对TP53和RB1的双性失活是SCLC-AT中几乎普遍的发现.
针对EZH2,AURKA和DLL3的临床前干预措施显示,有可能逆转神经内分泌表型或增强免疫性.

结论:

从EGFR突变LUAD转变为SCLC目前被认为是遗传和表观遗传不可逆转的.
针对特定的途径 (EZH2,AURKA,DLL3) 提供了潜在的治疗策略.
未来使用多omics技术的研究对早期检测和精确疗法开发至关重要,以改善患者的治疗结果.

关键词:

欧洲农业基金会 (EGFR) 是一个基金.肺部腺癌瘤是肺部腺癌.小细胞肺癌是一种小细胞肺癌.治疗性耐药性是一种治疗性耐药性.变化转化转化转化

更多相关视频

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

相关概念视频

Cancers Originate from Somatic Mutations in a Single Cell

Cancers Originate from Somatic Mutations in a Single Cell

Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...

Adaptive Mechanisms in Cancer Cells

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...